Phosphodiesterases synthesis

Increased lipid synthesis/inhibi-tion of lipolysis Activation of lipoprotein lipase (LPL)/induc-tion of fatty acid synthase (FAS)/inactivation of hormone sensitive lipase (HSL) Facilitated uptake of fatty acids by LPL-dependent hydrolysis of triacylglycerol from circulating lipoproteins. Increased lipid synthesis through Akt-mediated FAS-expression. Inhibition of lipolysis by preventing cAMP-dependent activation of HSL (insulin-dependent activation of phosphodiesterases )... 

Therefore, it is currently believed that anandamide is formed from membrane phospholipids (Fig. 4) through a pathway that involves (1) a trans-acylation of the amino group of phosphatidylethanolamine with arachidonate from the sn-1 position of phosphatidylcholine and (2) a D-type phosphodiesterase activity on the resulting A-arachidonylphosphati-dylethanolamide (NAPE). Synthesis of anandamide is presumably regulated at the levels of both enzymes, the A-acyltranferase and the phospholipase D, by stimuli that raise intracellular calcium or by receptors linked with cAMP and PKA. It has been shown that anandamide is formed when neurons are depolarized and, therefore, the intracellular calcium ion levels are elevated (Cadas, 1996). 

Takakusa, H., Kikuchi, K., Urano, Y., Sakamoto, S., Yamaguchi, K. and Nagano, T. (2002). Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer. J. Am. Chem. Soc. 124, 1653-1657. 

The solid phase parallel synthesis of tetrahydroim idazo[ 1,2-a] [ 1,3,5J tri azep i n-2-thiones and 2-imines has been reported starting from resin-bound peptides <06JCO127>. Pyrazolo[T,5 l,6]pyrimido[4,5-cfjpyridazinones with potent and selective phosphodiesterase 5 (PDEj) inhibitory activity have been described <06JMC5363>... 

Activation of adenylyl cyclase by an activated G-protein coupled receptor results in the synthesis of cAMP. The cAMP activates a downstream kinase, protein kinase A. Phosphodiesterase hydrolyzes and inactivates the cAMP. 

Cyclic nucleotides (cAMP and cGMP) are hydrolyzed to destroy the signal. The enzyme that hydrolyzes them is called a phosphodiesterase (more formally, a cAMP or cGMP phosphodiesterase). The signal that activates the synthesis of the cyclic nucleotide will often inhibit the phosphodiesterase. 

Calmodulin, a calcium binding protein, is involved in Ca2+-dependent regulation of several synaptic functions of the brain synthesis, uptake and release of neurotransmitters, protein phosphorylation and Ca+2 transport. It reacts with TET, TMT and TBT which then inactivates enzymes like Ca+2-ATPase and phosphodiesterase. In vitro studies indicated TBT was greater at inhibiting calmodulin activity than TET and TMT, whereas in vivo the order was TET > TMT > TBT. This may be due to the greater detoxification of TBT (66%) in the liver before moving to other organs30,31. 

FIGURE 21-2 Chemical pathways for the synthesis and degradation of cAMP. cAMP is synthesized from ATP by the enzyme adenylyl cyclase with the release of pyrophosphate, and is hydrolyzed into 5 -AMP by the enzyme phosphodiesterase. Both reactions require Mg2. Analogous reactions underlie the synthesis and degradation of cGMP (not shown). PP, inorganic pyrophosphate. 

But now, a strategy, used for the synthesis of derivative (622) (lit. synthesis (622) see in Ref. 555), which is the most efficient analog of the commercial drug rolipram with a broad spectrum of action (in particular, anti-inflammatory, antidepressant, neuroprotective, and immunodepressing effects), is presented in Scheme 3.286. (The principle action of rolipram is based on selective inhibition of adenosine monophosphate (AMP)-specific phosphodiesterase.) Derivative (622) is almost 10 times more efficient than rolipram, but the biological activity of (622) was determined only for the racemate (555). 

Using phosphotriester methods, dinucleoside (3 - 50-monophosphates containing 6-methyl-2,-deoxyuridine at the 3 - or 5 -end have been prepared.44 N.m.r. spectroscopy indicates that this nucleoside possesses the syn conformation in these compounds, and, on treatment with snake venom phosphodiesterase, d(m6UpT) is degraded, while d(Apm6U) is not, indicating that this enzyme, a 3 -exonuclease, requires the anti conformation to be present in the substrate. Two modified nucleo-side-5 -monophosphates, (20) and (21), which are resistant to 5 -nucleotidase, have been isolated from tRNA snake venom hydrolysates.45 A synthesis of (20) has been reported.46... 

One of the very first papers reporting about endo-linkers was published by Elmore et al. (Scheme 10.4) [13]. They described a new linker containing a phos-phodiester group (19) for solid-phase peptide synthesis using a Pepsyn K (polyacrylamide) resin. After completion of coupling and deprotection cycles, the phos-phodiester (20) was cleaved with a phosphodiesterase. In this way / -casomorphin. Leu-enkephalin and a collagenase substrate (21) were synthesized in high yields. 

Scheme 10.4 Synthesis of a collagenase substrate on a phosphodiesterase-scissile Linker.

In contrast to glucagon, the peptide hormone insulin (see p. 76) increases glycogen synthesis and inhibits glycogen breakdown. Via several intermediates, it inhibits protein kinase GSK-3 (bottom right for details, see p. 388) and thereby prevents inactivation of glycogen synthase. In addition, insulin reduces the cAMP level by activating cAMP phosphodiesterase (PDE). 

Figure 14-2. Regulation of cyclic AMP-dependent protein kinase A (PKA) by cyclic AMP. Activation of adenylate cyclase by binding of G( -GTP amplifies the signal by synthesis of many molecules of cyclic AMP. Cyclic AMP binding to PKA causes dissociation of the regulatory subunits from the catalytic subunits, which carry on the signal. Phosphodiesterase regulates the concentration of cyclic AMP by catalyzing its hydrolysis to AMP, which shuts off the signal.

D. Etanercept is a recombinant fusion protein consisting of two TNF receptor domains linked to one IgG Fc molecule. It binds to soluble TNF-a and TNF-(3 and forms inactive complexes. It does not directly affect cAMP phosphodiesterase, leukotriene synthesis, or autoantibody production. 

Concentration of cAMP is controlled primarily by two means, namely via new synthesis by adenylyl cyclase and degradation by phosphodiesterases (review Houslay Milligan, 1997). In addition to adenylyl cyclase, the activity of which is subject to diverse regulation (see 5.6.1), the cAMP phosphodiesterases are also an important point of attack for control of the cAMP level. There are phosphodiesterases regulated by Ca Vcahnoduhn and by protein phosphorylation. More than 10 different isoforms of phosphodiesterase are known, which vary in their cyclic nucleotide specificity and in their regulation. 

---